Current State and Future Directions in the Therapy of ALS
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disorder affecting upper and lower motor neurons, with death resulting mainly from respiratory failure three to five years after symptom onset. As the exact underlying causative pathological pathway is unclear and potentially diverse, finding a suitable therapy to slow down or possibly stop disease progression remains challenging. Varying by country Riluzole, Edaravone, and Sodium phenylbutyrate/Taurursodiol are the only drugs currently approved in ALS treatment for their moderate effect on disease progression. Even though curative treatment options, able to prevent or stop disease progression, are still unknown, recent breakthroughs, especially in the field of targeting genetic disease forms, raise hope for improved care and therapy for ALS patients. In this review, we aim to summarize the current state of ALS therapy, including medication as well as supportive therapy, and discuss the ongoing developments and prospects in the field. Furthermore, we highlight the rationale behind the intense research on biomarkers and genetic testing as a feasible way to improve the classification of ALS patients towards personalized medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High-Resolution Profiling of Histone Methylations in the Human Genome
Barski, A., Cuddapah, S., Cui, K., Roh, T.-Y., Schones, D. E., Wang, Z., Wei, G., Chepelev, I., & Zhao, K. (2007) · Cell · doi:10.1016/j.cell.2007.05.009 · Cited by 6,845
Cedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00210-5 · Cited by 3,307
Combinatorial patterns of histone acetylations and methylations in the human genome
Wang, Z., Zang, C., Rosenfeld, J. A., Schones, D. E., Barski, A., Cuddapah, S., Cui, K., Roh, T.-Y., Peng, W., Zhang, M. Q., et al. (2008) · Nature Genetics · doi:10.1038/ng.154 · Cited by 2,331
The Endocannabinoid System as an Emerging Target of Pharmacotherapy
Pacher, P., Bátkai, S., & Kunos, G. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.3.2 · Cited by 2,077
Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes
Wang, Z., Zang, C., Cui, K., Schones, D. E., Barski, A., Peng, W., & Zhao, K. (2009) · Cell · doi:10.1016/j.cell.2009.06.049 · Cited by 1,344
Neurofilament light chain as a biomarker in neurological disorders
Gaetani, L., Blennow, K., Calabresi, P., Di Filippo, M., Parnetti, L., & Zetterberg, H. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-320106 · Cited by 1,334
The EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis:, Andersen, P. M., Abrahams, S., Borasio, G. D., de Carvalho, M., Chio, A., Van Damme, P., Hardiman, O., Kollewe, K., Morrison, K. E., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03501.x · Cited by 1,117
The C9orf72 repeat expansion disrupts nucleocytoplasmic transport.
Zhang, K., Donnelly, C. J., Haeusler, A. R., Grima, J. C., Machamer, J. B., Steinwald, P., Daley, E. L., Miller, S. J., Cunningham, K. M., Vidensky, S., et al. (2015) · Nature · doi:10.1038/nature14973 · Cited by 982
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Miller, T. M., Cudkowicz, M. E., Genge, A., Shaw, P. J., Sobue, G., Bucelli, R. C., Chiò, A., Van Damme, P., Ludolph, A. C., Glass, J. D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204705 · Cited by 966
Jovičić, A., Mertens, J., Boeynaems, S., Bogaert, E., Chai, N., Yamada, S. B., Paul, J. W., Sun, S., Herdy, J. R., Bieri, G., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4085 · Cited by 598
A high-performance speech neuroprosthesis
Willett, F. R., Kunz, E. M., Fan, C., Avansino, D. T., Wilson, G. H., Choi, E. Y., Kamdar, F., Glasser, M. F., Hochberg, L. R., Druckmann, S., et al. (2023) · Nature · doi:10.1038/s41586-023-06377-x · Cited by 581
Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice
Becker, L. A., Huang, B., Bieri, G., Ma, R., Knowles, D. A., Jafar-Nejad, P., Messing, J., Kim, H. J., Soriano, A., Auburger, G., et al. (2017) · Nature · doi:10.1038/nature22038 · Cited by 571
Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons
Shi, Y., Lin, S., Staats, K. A., Li, Y., Chang, W.-H., Hung, S.-T., Hendricks, E., Linares, G. R., Wang, Y., Son, E. Y., et al. (2018) · Nature Medicine · doi:10.1038/nm.4490 · Cited by 566
Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
Miller, T., Cudkowicz, M., Shaw, P. J., Andersen, P. M., Atassi, N., Bucelli, R. C., Genge, A., Glass, J., Ladha, S., Ludolph, A. L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2003715 · Cited by 565
Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
Paganoni, S., Macklin, E. A., Hendrix, S., Berry, J. D., Elliott, M. A., Maiser, S., Karam, C., Caress, J. B., Owegi, M. A., Quick, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916945 · Cited by 536
Mead, R. J., Shan, N., Reiser, H. J., Marshall, F., & Shaw, P. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00612-2 · Cited by 505 · cited 3×
“Oxidative stress, excitotoxicity, mitochondrial and proteasomal dysfunctions, RNA metabolism, altered synaptic function, disturbed axonal transport, and neuroinflammation are, among other pathways, considered as important contributors to ALS disease development [10,11].”
BackgroundALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment?
Petrov, D., Mansfield, C., Moussy, A., & Hermine, O. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00068 · Cited by 451 · cited 1×
“First, most preclinical trials on mouse models have been tested in SOD1 models before transitioning to human testing [12,13].”
BackgroundOlney, N. T., Spina, S., & Miller, B. L. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.008 · Cited by 419
A brain-computer interface for long-term independent home use
Sellers, E. W., Vaughan, T. M., & Wolpaw, J. R. (2010) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482961003777470 · Cited by 400
HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients
Guo, W., Naujock, M., Fumagalli, L., Vandoorne, T., Baatsen, P., Boon, R., Ordovás, L., Patel, A., Welters, M., Vanwelden, T., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00911-y · Cited by 373
The epidemiology of amyotrophic lateral sclerosis
(2016) · Handbook of Clinical Neurology · doi:10.1016/b978-0-12-802973-2.00013-6 · Cited by 353
Ryu, H., Smith, K., Camelo, S. I., Carreras, I., Lee, J., Iglesias, A. H., Dangond, F., Cormier, K. A., Cudkowicz, M. E., H. Brown, R., et al. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03077.x · Cited by 353
SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS
Mueller, C., Berry, J. D., McKenna-Yasek, D. M., Gernoux, G., Owegi, M. A., Pothier, L. M., Douthwright, C. L., Gelevski, D., Luppino, S. D., Blackwood, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2005056 · Cited by 264
Redman, M., King, A., Watson, C., & King, D. (2016) · Archives of disease in childhood - Education & practice edition · doi:10.1136/archdischild-2016-310459 · Cited by 248
Independent home use of a brain-computer interface by people with amyotrophic lateral sclerosis
Wolpaw, J. R., Bedlack, R. S., Reda, D. J., Ringer, R. J., Banks, P. G., Vaughan, T. M., Heckman, S. M., McCane, L. M., Carmack, C. S., Winden, S., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005812 · Cited by 170
Stefanova, N., Georgievska, B., Eriksson, H., Poewe, W., & Wenning, G. K. (2012) · Neurotoxicity Research · doi:10.1007/s12640-011-9294-3 · Cited by 111
Fazal, R., Boeynaems, S., Swijsen, A., De Decker, M., Fumagalli, L., Moisse, M., Vanneste, J., Guo, W., Boon, R., Vercruysse, T., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2020106177 · Cited by 108
Psychotherapy Targeting Depression and Anxiety for Use in Palliative Care: A Meta-Analysis.
Fulton, J. J., Newins, A. R., Porter, L. S., & Ramos, K. (2018) · Journal of Palliative Medicine · doi:10.1089/jpm.2017.0576 · Cited by 97 · cited 2×
“Psychotherapy can alleviate depression and anxiety as studies on palliative care suggest and should therefore be offered, but there are only a few ALS-specific studies on this topic [63,64].”
BackgroundRobinson, A. P., Zhang, J. Z., Titus, H. E., Karl, M., Merzliakov, M., Dorfman, A. R., Karlik, S., Stewart, M. G., Watt, R. K., Facer, B. D., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-58709-w · Cited by 87
Genetics of Amyotrophic Lateral Sclerosis
Gregory, J. M., Fagegaltier, D., Phatnani, H., & Harms, M. B. (2020) · Current Genetic Medicine Reports · doi:10.1007/s40142-020-00194-8 · Cited by 83 · cited 1×
“Many altered pathways and genetic mutations have been discovered and associated with ALS which makes it, up to date, impossible to find “the one” cause for the disease, and the one therapy to suit all [15,26].”
BackgroundBody Mass Index and Amyotrophic Lateral Sclerosis: A Study of US Military Veterans
Mariosa, D., Beard, J. D., Umbach, D. M., Bellocco, R., Keller, J., Peters, T. L., Allen, K. D., Ye, W., Sandler, D. P., Schmidt, S., et al. (2017) · American Journal of Epidemiology · doi:10.1093/aje/kww140 · Cited by 67
Chen, Y., Wang, H., Ying, Z., & Gao, Q. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.03.051 · Cited by 63
Ortega-Hombrados, L., Molina-Torres, G., Galán-Mercant, A., Sánchez-Guerrero, E., González-Sánchez, M., & Ruiz-Muñoz, M. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18031074 · Cited by 62 · cited 1×
“Moderate active physical therapy has been shown to have a positive impact on the stabilization and maintenance of physical activity and ALSFRS-R levels when compared to passive therapy [16,65].”
BackgroundBurg, T., Rossaert, E., Moisse, M., Van Damme, P., & Van Den Bosch, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011224 · Cited by 50
Gould, R. L., Coulson, M. C., Brown, R. G., Goldstein, L. H., Al-Chalabi, A., & Howard, R. J. (2015) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2015.1062515 · Cited by 47
Cited by
Gao, L., Wang, J., & Bi, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s549893 · Cited by 52
Zheng, X., Yuan, W., Li, L., Ma, H., Zhu, M., Li, X., & Feng, X. (2025) · European Journal of Medical Research · doi:10.1186/s40001-025-02937-1 · Cited by 9
“Certainly, locomotor system dysfunction is the most prominent clinical manifestations of ALS, ultimately leading to respiratory failure approximately 3–5 years after symptom onset [102].”
Huang, Q., Zhang, Q., & Cao, B. (2024) · Brain and Behavior · doi:10.1002/brb3.3543 · Cited by 9
Metadata
- Authors
- Tzeplaeff, L., Wilfling, S., Requardt, M. V., & Herdick, M.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2023-05-31
- Volume
- 12
- Issue
- 11
- Pages
- 1523
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W4379057325
- Cited by
- 148
- References
- 35
- FWCI
- 21.62
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.